Meeting
2021 Genitourinary Cancers Symposium
The comparison of cytoreductive nephrectomy (CN) with tyrosine kinase inhibitor therapy alone in patients with primary metastatic renal cell carcinoma (mRCC).
Authors
Shingo Hatakeyama
Hirosaki University, Hirosaki, Japan
Shingo Hatakeyama , Sei Naito , Kazuyuki Numakura , Renpei Kato , Tomoyuki Koguchi , Takahiro Kojima , Yoshihide Kawasaki , Kandori Kandori , Eiki Tsushima , Hiroyuki Nishiyama , Akihiro Ito , Yoshiyuki Kojima , Tomonori Habuchi , Wataru Obara , Norihiko Tsuchiya , Chikara Ohyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 304)
DOI
10.1200/JCO.2021.39.6_suppl.304
Abstract #
304
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).
First Author: Guillermo de Velasco
Poster
2024 ASCO Genitourinary Cancers Symposium
Linear muscle segmentation for metastatic renal cell carcinoma.
First Author: Edouard Nicaise
First Author: Olivia French Gordon
Poster
2023 ASCO Genitourinary Cancers Symposium
Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).
First Author: Aitzaz Qaisar